You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD30 Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Relapse/Recurrence Trial in Wuhan, Nanchang (CD30 CAR-T, Camrelizumab)

Recruiting
  • Lymphoma
  • Relapse/Recurrence
  • Wuhan, Hubei, China
  • +1 more
Apr 8, 2022

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 13, 2023

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • GEN3017
  • (no location specified)
Aug 25, 2023

Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Houston (autologous CAR.CD30 EBV specific-CTLs)

Active, not recruiting
  • Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • autologous CAR.CD30 EBV specific-CTLs
  • Houston, Texas
  • +1 more
Feb 4, 2022

Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

Recruiting
  • Lymphoma
  • +7 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022

A Study of People With CD30 Positive Lymphoma in China

Not yet recruiting
  • Lymphoma
    • (no location specified)
    Aug 17, 2022

    Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

    Recruiting
    • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
    • Classical Hodgkin Lymphoma
    • CD30.CAR-EBVST cells
    • Houston, Texas
    • +1 more
    Jul 20, 2022

    Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

    Active, not recruiting
    • Peripheral T Cell Lymphoma
    • Pediatric Hodgkin Lymphoma
    • Brentuximab Vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Oct 11, 2022

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

    Withdrawn
    • T Cell Lymphoma
    • Brentuximab Vedotin
    • Kansas City, Kansas
      The University of Kansas Cancer Center, Westwood Campus
    Feb 1, 2023

    Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning)

    Active, not recruiting
    • Hodgkin Lymphoma
    • Brentuximab Vedotin
    • +2 more
    • Valhalla, New York
      New York Medical College
    Oct 24, 2022

    Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified Trial in Hangzhou (Anti CD30 CAR-T Cell Injection)

    Not yet recruiting
    • Hodgkin Lymphoma
    • +7 more
    • Anti CD30 CAR-T Cell Injection
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, College of medicine, Zhejiang Uni
    Jan 12, 2022

    Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Trial in Chapel Hill, Houston (CAR.CD30 T cells)

    Active, not recruiting
    • Non-Hodgkin's Lymphoma
    • Hodgkin's Lymphoma
    • CAR.CD30 T cells
    • Chapel Hill, North Carolina
    • +2 more
    Mar 16, 2022

    Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)

    Recruiting
    • Peripheral T Cell Lymphoma
    • ATLCAR.CD30 T cells
    • +3 more
    • Chapel Hill, North Carolina
    • +1 more
    Mar 4, 2022

    T-Cell Lymphoma Trial (Brentuximab vedotin)

    Not yet recruiting
    • T-Cell Lymphoma
    • Brentuximab vedotin
    • (no location specified)
    Jun 30, 2022

    Brentuximab Vedotin Intravenous Infusion "Untreated

    Active, not recruiting
    • Untreated CD30-Positive Hodgkin's Lymphoma
    • Brentuximab vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Mar 24, 2022

    Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

    Not yet recruiting
    • Cancer
    • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
    • Fludarabine (30 mg/m^2)
    • +2 more
    • (no location specified)
    Jul 25, 2023

    Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)

    Not yet recruiting
    • Lymphoma
    • Brentuximab Vedotin
    • +3 more
    • Beijing, China
    • +15 more
    Jan 4, 2023

    Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory Trial in United States (CD30.CAR-T, Fludarabine,

    Active, not recruiting
    • Hodgkin Lymphoma, Adult
    • +3 more
    • Duarte, California
    • +4 more
    Apr 3, 2022

    Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent Trial in United States (Nivolumab, Autologous

    Recruiting
    • Classical Hodgkin Lymphoma
    • +2 more
    • Duarte, California
    • +4 more
    Jun 27, 2022

    Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

    Recruiting
    • Relapsed Hodgkin Lymphoma
    • Refractory Hodgkin Lymphoma
    • Nivolumab
    • Pembrolizumab
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Jul 22, 2022

    Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

    Recruiting
    • Recurrent Anaplastic Large Cell Lymphoma
    • +9 more
    • Anti-CD30/CD16A Monoclonal Antibody AFM13
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022